4th company debut! More than 7.5 billion varieties of the market to meet the change.

On August 20th, the official website of the State Drug Administration issued the certificate of approval of drugs to be received information announcement shows that 22 approvals issued on August 17th are to be collected.
including Koren Pharmaceuticals injection yew alcohol (albumin-binding type), has been officially approved for listing, becoming the fourth domestic after Stone Pharmaceutical Group, Hengrui Pharmaceuticals, Qilu Pharmaceuticals.
market potential is huge due to the cytotoxic anti-tumor principle of yew alcohol, in many tumors in the course of treatment has a good chemotherapy effect, its adaptability is still expanding.
data from public medical institutions in 2019, yew alcohol performed well in anti-tumor injections, with sales growth of 35.87 percent.
In 2019, more than 1 billion varieties of anti-tumor injections (Source: Minet Database) as a new special targeting agent for yew alcohol, which is used to treat metastatic breast cancer with failed combined chemotherapy or breast cancer that relapses within 6 months of assisted chemotherapy.
the drug was developed by Abraxis, which was acquired by Celgene in 2010 and the global market has stabilized at around $1 billion a year in recent years.
Because the formula does not contain polyoxyethylene castor oil, and through albumin nanoparticle-carrying technology to improve the concentration of yew alcohol in tumor tissue, compared with traditional yew alcohol preparations, injection of yew alcohol (albumin binding type) has less allergic reactions, higher dosage, higher dose The advantages of faster drug use and no pre-treatment before use are currently recommended by the National Comprehensive Cancer Network (NCCN) Guidelines for Clinical Practice for Breast Cancer 2020.V5, and the China Society for Clinical Oncology (CSCO) Guidelines for Breast Cancer Diagnosis and Treatment 2020.
increasingly fierce competition from the recent changes in market share, it can also be seen that the market size of yew alcohol (albumin-binding type) is expanding rapidly. According to
meters intranet data, in 2019 China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) terminal yew alcohol sales of more than 7.5 billion yuan, injection yew alcohol (albumin-binding) market share increased from 7.6% in 2013 to 38.6% in 2019.
in the second batch of national mining, injection of yew alcohol (albumin binding type) in the selection of enterprises for the new base, stone medicine group, Hengrui medicine 3.
Andever, in March this year, the State Drug Administration announced that it would suspend the import, sale and use of Xinji in China because some of its key production facilities do not meet the basic requirements of quality management of China's pharmaceutical production.
jointly to cancel the original research of the selection of eligibility, the market selected by the stone medicine group, Hengrui pharmaceutical division.
at present, there are still Positive Day Qing Pharmaceutical Group, Haizheng Pharmaceuticals, Kangyu Bio, Yangzijiang Pharmaceutical Group's injection yew alcohol (albumin binding type) listing application is under review.
The application for listing of injection yew alcohol (albumin-binding type) in the review enterprises (source: Minet database) in addition, according to the 2020 National Health Insurance Drug Catalog Adjustment Work Programme planning adjustment scope, as a second batch of collected varieties of injectable yew alcohol (albumin-binding type) has been included in the 2020 drug catalog proposed new drug scope.
is not difficult to speculate that the market competition will intensify as the subsequent market for injections of yew alcohol (albumin-binding type) progresses.
.